ATRN-333

ATRN-333 is a next-generation macrocyclic inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), developed to sensitize glioblastoma (GBM) tumors to lomustine, an oral DNA alkylating agent. Preclinical studies have shown that ATRN-333 effectively sensitizes both flank and intracranial GBM tumors to lomustine, enhancing the anti-tumor effect of this chemotherapy. Both free and nanoparticle-encapsulated forms of ATRN-333 demonstrate high potency in inhibiting ATR function in cell-based assays. The drug is being developed by Aprea Therapeutics as part of their synthetic lethality oncology pipeline[1][3][9].